Bob Hombach

Track

Insider profile

Currently holds positions in Baxalta Inc, Biomarin Pharmaceutical Inc, Carmax Inc and Aptinyx Inc

Performance

Overall performance
Performance over holding periods
30 days 90 days 120 days
Average return 17% 8.2% 15.1%
Success rate 100% 68% 82%
Transactions
1 100% Buy
34 71% Buy
47 69% Buy
Ranking by holding-period performance

Positions

Position Company Period
Chief Financial Officer, Chief Operating Officer, Executive Vice President Baxalta Inc None -
Independent Director Biomarin Pharmaceutical Inc Sept. 28, 2017 -
Independent Director Carmax Inc April 1, 2018 -
Independent Director Aptinyx Inc May 1, 2018 -
Chief Financial Officer, Corporate Vice President Baxter International Inc March 23, 2011 - Jan. 1, 2015
Bob Hombach's trades of Seaport Therapeutics Inc's stock


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date Company B/S Transaction type Nb. shares
Price
Value 		Number of shares Price Value Details
2026-06-24 2026-06-22
B Purchase
35,113 +39.2%
83.22
US$4,610,786 		35,113 +39.2% 83.22 US$4,610,786
2021-11-15 2021-11-12
US Aptinyx Inc (APTX)
B Purchase
99,154 +40.4%
333.96
US$2,817,602 		99,154 +40.4% 333.96 US$2,817,602
2021-11-15 2021-11-11
US Aptinyx Inc (APTX)
B Purchase
54,365 +5.0%
68.69
US$3,057,442 		54,365 +5.0% 68.69 US$3,057,442
2020-01-14 2020-01-10
US Aptinyx Inc (APTX)
B Purchase
50,000 +56.1%
3.00
US$150,000 		50,000 +56.1% 3.00 US$150,000
2019-01-28 2019-01-25
US Aptinyx Inc (APTX)
B Purchase
11,655 +31.1%
5.54
US$64,569 		11,655 +31.1% 5.54 US$64,569
2019-01-28 2019-01-24
US Aptinyx Inc (APTX)
B Purchase
13,345 +55.4%
5.52
US$73,664 		13,345 +55.4% 5.52 US$73,664